Treamid Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • 2ndary - Private

Treamid Therapeutics General Information

Description

Developer of chemical entities designed to treat inflammatory respiratory and endocrine diseases. The company investigates the mode and mechanism of action of their patent-protected chemical substances regarding their therapeutic potential in the treatment of airway diseases, enabling patients to get treated by innovative and easily accessible medications.

Contact Information

Website
www.treamid.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Robert-Rössle-Straße 10
  • Haus 80 (Otto-Warburg-Haus)
  • 13125 Berlin
  • Germany
Primary Industry
Drug Discovery
Corporate Office
  • Robert-Rössle-Straße 10
  • Haus 80 (Otto-Warburg-Haus)
  • 13125 Berlin
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Treamid Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-Dec-2020 Completed Clinical Trials - Phase 1
1. Early Stage VC 04-Jan-2017 Completed Startup
To view Treamid Therapeutics’s complete valuation and funding history, request access »

Treamid Therapeutics Patents

Treamid Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4818160-A1 Salts and salt hydrates of n,n'-bis[2-(1h-imidazol-4-yl)ethyl] oxalamide for the treatment of cough and fibrosis of lungs, liver, kidneys, pancreas, and heart Pending 02-Apr-2025
WO-2026210001-A1 Salts and salt hydrates of n,n'-bis[2-(1h-imidazol-4-yl)ethyl]oxalamide for the treatment of diseases accompanied by fibrotic formations and/or cough Pending 02-Apr-2025
WO-2023177328-A1 Bisamide derivative of dicarboxylic acid for use in restoring the external respiratory function after coronavirus infection Inactive 17-Mar-2022
AU-2016266439-A1 Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function Active 27-May-2015
AU-2016266439-B2 Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function Active 27-May-2015 A61K31/4164
To view Treamid Therapeutics’s complete patent history, request access »

Treamid Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Treamid Therapeutics FAQs

  • When was Treamid Therapeutics founded?

    Treamid Therapeutics was founded in 2016.

  • Where is Treamid Therapeutics headquartered?

    Treamid Therapeutics is headquartered in Berlin, Germany.

  • What is the size of Treamid Therapeutics?

    Treamid Therapeutics has 3 total employees.

  • What industry is Treamid Therapeutics in?

    Treamid Therapeutics’s primary industry is Drug Discovery.

  • Is Treamid Therapeutics a private or public company?

    Treamid Therapeutics is a Private company.

  • What is Treamid Therapeutics’s current revenue?

    The current revenue for Treamid Therapeutics is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process